MX2021014402A - Dispersion de solidos y metodo de preparacion de los mismos. - Google Patents

Dispersion de solidos y metodo de preparacion de los mismos.

Info

Publication number
MX2021014402A
MX2021014402A MX2021014402A MX2021014402A MX2021014402A MX 2021014402 A MX2021014402 A MX 2021014402A MX 2021014402 A MX2021014402 A MX 2021014402A MX 2021014402 A MX2021014402 A MX 2021014402A MX 2021014402 A MX2021014402 A MX 2021014402A
Authority
MX
Mexico
Prior art keywords
solid dispersion
preparation
method therefor
difluorophenoxy
ynyl
Prior art date
Application number
MX2021014402A
Other languages
English (en)
Inventor
Zhenxing Du
Jie Wang
Xianqiang Zhou
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2021014402A publication Critical patent/MX2021014402A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Colloid Chemistry (AREA)

Abstract

Dispersión sólida y método de preparación de la misma. En una modalidad específica, la dispersión sólida contiene un ingrediente activo (R) -4-amino-1- (1- (but-2-inil) pirrolidin-3-il))-3-(4- (2,6-difluorofenoxi) fenil) -1,6-dihidro-7H-pirrolo [2,3-d] piridazin-7-ona o una sal del mismo, y un material portador, y se ajusta el valor de pH; el empleo de un método que añade una cantidad apropiada de ácido inhibe eficazmente un fenómeno de emulsificación en un proceso de disolvente inverso, obteniendo así una dispersión sólida que tiene un tamaño de partícula moderado y un contenido uniforme.
MX2021014402A 2019-05-31 2020-05-29 Dispersion de solidos y metodo de preparacion de los mismos. MX2021014402A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910468254 2019-05-31
PCT/CN2020/093206 WO2020239065A1 (zh) 2019-05-31 2020-05-29 一种固体分散体及其制备方法

Publications (1)

Publication Number Publication Date
MX2021014402A true MX2021014402A (es) 2022-02-14

Family

ID=73553512

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014402A MX2021014402A (es) 2019-05-31 2020-05-29 Dispersion de solidos y metodo de preparacion de los mismos.

Country Status (12)

Country Link
US (1) US20220233449A1 (es)
EP (1) EP3977997A4 (es)
JP (1) JP2022534610A (es)
KR (1) KR20220016116A (es)
CN (1) CN113825511A (es)
AU (1) AU2020282470A1 (es)
BR (1) BR112021023691A2 (es)
CA (1) CA3141921A1 (es)
MX (1) MX2021014402A (es)
TW (1) TW202100527A (es)
WO (1) WO2020239065A1 (es)
ZA (1) ZA202110055B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023182332A1 (ja) * 2022-03-22 2023-09-28 株式会社ダイセル 口腔内崩壊錠用の添加剤組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100087444A1 (en) * 2007-03-12 2010-04-08 Dr. Reddy's Laboratories Ltd. Imatinib mesylate
PE20151335A1 (es) * 2013-01-22 2015-09-18 Hoffmann La Roche Composicion farmaceutica con biodisponibilidad mejorada
CA2953798C (en) 2014-07-07 2019-06-11 Eternity Bioscience Inc. Aminopyridazinone compounds as protein kinase inhibitors
WO2016082705A1 (zh) * 2014-11-27 2016-06-02 华东理工大学 一种难溶性活性成分微粒、微粒制剂及其制备方法
WO2016088074A1 (en) * 2014-12-03 2016-06-09 Dr. Reddy’S Laboratories Limited Process for the preparation of amorphous ibrutinib
CN106924262A (zh) * 2015-12-31 2017-07-07 常州方楠医药技术有限公司 一种无定型托法替尼枸橼酸盐与药用辅料的固体分散体及其制备方法
CN107406453B (zh) * 2016-01-05 2018-12-28 江苏恒瑞医药股份有限公司 一种btk激酶抑制剂的结晶形式及其制备方法
IN201621020494A (es) * 2016-06-15 2017-12-22
KR20200024237A (ko) * 2017-07-04 2020-03-06 지앙수 헨그루이 메디슨 컴퍼니 리미티드 약학 조성물 및 이를 제조하기 위한 방법

Also Published As

Publication number Publication date
ZA202110055B (en) 2023-04-26
AU2020282470A1 (en) 2022-01-27
KR20220016116A (ko) 2022-02-08
TW202100527A (zh) 2021-01-01
EP3977997A1 (en) 2022-04-06
CA3141921A1 (en) 2020-12-03
EP3977997A4 (en) 2022-07-27
WO2020239065A1 (zh) 2020-12-03
CN113825511A (zh) 2021-12-21
US20220233449A1 (en) 2022-07-28
BR112021023691A2 (pt) 2022-04-12
JP2022534610A (ja) 2022-08-02

Similar Documents

Publication Publication Date Title
WO2019112899A3 (en) IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS
RU2416611C2 (ru) Бициклические амиды как ингибиторы киназы
MX2022000553A (es) Modificación de células efectoras inmunitarias y uso de las mismas.
MX2020009896A (es) Celulas efectoras inmunitarias modificadas y usos de las mismas.
JOP20220100A1 (ar) مركبات هتيروماتية ثنائية الحلقة مندمجة نشطة من الناحية المبيدة للآفات
MX2021012290A (es) Compuestos de diazina-amida activos como pesticidas.
GEP20084341B (en) Aminoheteroaryl compounds as protein kinase inhibitors
ATE289902T1 (de) Azol/amin oxid holzschutzmittel und fungizide
MX2021011771A (es) Compuestos de diazina-amida activos como pesticidas.
WO2019157280A3 (en) Collaborative editing of media in a mixed computing environment
MX2007003908A (es) Nuevos insecticidas.
GEP20227429B (en) Salts of pyrrolotriazine derivatives useful as tam inhibitors
BRPI0518154A (pt) composição conservante de madeira, e, método para conservar um produto de madeira
JOP20220010A1 (ar) مشتقات 6، 7-داي هيدرو-5H-بيريدو[2، 3-c]بيريدازين والمركبات ذات الصلة كمثبطات لبروتين BCL-XL وعوامل مساعدة على تلاشي الخلايا لعلاج السرطان
CA2366932A1 (en) Cyclic protein tyrosine kinase inhibitors
SI3009428T1 (en) DIAMINO HETEROCYCLIC CARBOSAMIDE COMPOUNDS
IL275059A (en) 5-(2-(5,2-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo[5,1-A]pyrimidine derivatives and related compounds as TRK kinase inhibitors for cancer therapy
BR0308030A (pt) Derivados de 5-feniltiazol e uso como inibidores de pi3 cinase
MX2021014402A (es) Dispersion de solidos y metodo de preparacion de los mismos.
ZA941714B (en) Novel heterocycles their preparation and their use
AU4761100A (en) Methods and materials for generating sh3 domains with tailored binding properties
GB0320020D0 (en) Improved formulation for providing an enteric coating material
IL171875A0 (en) Pioglitazone salts,such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
AU1783201A (en) 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
WO2003033499A3 (en) Inhibitors of cyclin-dependent kinases, compositions and uses related thereto